MARKET

BRTX

BRTX

Biorestorative Therapies Inc
NASDAQ
0.2900
-0.0224
-7.17%
After Hours: 0.3006 +0.0106 +3.66% 19:59 07/24 EDT
OPEN
0.3116
PREV CLOSE
0.3124
HIGH
0.3225
LOW
0.2900
VOLUME
300.51K
TURNOVER
--
52 WEEK HIGH
1.890
52 WEEK LOW
0.1593
MARKET CAP
7.39M
P/E (TTM)
-0.2666
1D
5D
1M
3M
1Y
5Y
1D
BioRestorative Therapies files Form 3 initial beneficial ownership statement for director Steven Collier Brown
PUBT · 21h ago
Weekly Report: what happened at BRTX last week (0713-0717)?
Weekly Report · 5d ago
BioRestorative Therapies Overhauls Leadership and Board Governance
TipRanks · 07/17 08:51
BioRestorative Therapies Says Lance Alstodt Resigns As President, CEO, Chairman And All Other Positions Effective July 13, 2026; Robert Kristal Resigns As CFO And All Other Positions; Katharyn Field Appointed As CEO, President, And Interim CFO
Benzinga · 07/16 21:45
BIORESTORATIVE THERAPIES - LANCE ALSTODT RESIGNS AS PRESIDENT, CEO, CHAIRMAN AND ALL OTHER POSITIONS EFFECTIVE JULY 13, 2026 - SEC FILING
Reuters · 07/16 21:37
BIORESTORATIVE THERAPIES - APPOINTS KATHARYN FIELD AS CEO, PRESIDENT, AND INTERIM CFO EFFECTIVE JULY 13, 2026 - SEC FILING
Reuters · 07/16 21:37
BioRestorative CEO Lance Alstodt, CFO Robert Kristal resign effective immediately
PUBT · 07/16 21:31
Weekly Report: what happened at BRTX last week (0706-0710)?
Weekly Report · 07/13 09:17
More
About BRTX
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.

Webull offers BioRestorative Therapies Inc stock information, including NASDAQ: BRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRTX stock methods without spending real money on the virtual paper trading platform.